210 related articles for article (PubMed ID: 37516994)
81. [Use of chemotherapy in the treatment of aggresive pituitary adenomas].
Kobyakov GL; Chernov IV; Astafieva LI; Trunin YY; Poddubsky AA; Kalinin PL
Zh Vopr Neirokhir Im N N Burdenko; 2020; 84(1):69-75. PubMed ID: 32207745
[TBL] [Abstract][Full Text] [Related]
82. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
Ceccato F; Lombardi G; Manara R; Emanuelli E; Denaro L; Milanese L; Gardiman MP; Bertorelle R; Scanarini M; D'Avella D; Occhi G; Boscaro M; Zagonel V; Scaroni C
J Neurooncol; 2015 Mar; 122(1):189-96. PubMed ID: 25555563
[TBL] [Abstract][Full Text] [Related]
83. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas.
Dekkers OM; Pereira AM; Romijn JA
J Clin Endocrinol Metab; 2008 Oct; 93(10):3717-26. PubMed ID: 18682516
[TBL] [Abstract][Full Text] [Related]
84. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
[TBL] [Abstract][Full Text] [Related]
85. Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series.
Padovan M; Cerretti G; Caccese M; Barbot M; Bergo E; Occhi G; Scaroni C; Lombardi G; Ceccato F
Expert Rev Endocrinol Metab; 2023 Mar; 18(2):181-198. PubMed ID: 36876325
[TBL] [Abstract][Full Text] [Related]
86. Research advances on the immune research and prospect of immunotherapy in pituitary adenomas.
Nie D; Fang Q; Li B; Cheng J; Li C; Gui S; Zhang Y; Zhao P
World J Surg Oncol; 2021 Jun; 19(1):162. PubMed ID: 34090476
[TBL] [Abstract][Full Text] [Related]
87. Cystic versus non-cystic silent corticotrophic adenomas: clinical and histological analysis of 62 cases after microscopic transsphenoidal surgery-a retrospective, single-center study.
Sumislawski P; Huckhagel T; Krajewski KL; Aberle J; Saeger W; Flitsch J; Rotermund R
Sci Rep; 2023 Feb; 13(1):2468. PubMed ID: 36774403
[TBL] [Abstract][Full Text] [Related]
88. Nasopharyngeal presentation of pituitary tumors. Differential diagnosis and treatment.
van der Lely AJ; Knegt PP; Stefanko SZ; Tanghe HL; Singh R; Lamberts SW
J Clin Endocrinol Metab; 1992 Apr; 74(4):811-3. PubMed ID: 1548346
[TBL] [Abstract][Full Text] [Related]
89. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
Moshkin O; Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Uribe H; Gonzalez R; Cusimano M; Horvath E; Rotondo F; Kovacs K
Hormones (Athens); 2011; 10(2):162-7. PubMed ID: 21724542
[TBL] [Abstract][Full Text] [Related]
90. Pituitary adenomas: current methods of diagnosis and treatment.
Buatti JM; Marcus RB
Oncology (Williston Park); 1997 Jun; 11(6):791-6; discussion 798, 803-4. PubMed ID: 9189937
[TBL] [Abstract][Full Text] [Related]
91. [Aggressive and resistant-to-treatment pituitary tumors].
Cuny T; Chanson P
Ann Endocrinol (Paris); 2013 Oct; 74 Suppl 1():S3-12. PubMed ID: 24356289
[TBL] [Abstract][Full Text] [Related]
92. Radiation therapy in the multimodal treatment approach of pituitary adenoma.
Becker G; Kocher M; Kortmann RD; Paulsen F; Jeremic B; Müller RP; Bamberg M
Strahlenther Onkol; 2002 Apr; 178(4):173-86. PubMed ID: 12040754
[TBL] [Abstract][Full Text] [Related]
93. Treatment of nonfunctioning pituitary adenomas: what were the contributions of the last 10 years? A critical view.
Pereira AM; Biermasz NR
Ann Endocrinol (Paris); 2012 Apr; 73(2):111-6. PubMed ID: 22542000
[TBL] [Abstract][Full Text] [Related]
94. Pituitary adenomas: an overview.
Lake MG; Krook LS; Cruz SV
Am Fam Physician; 2013 Sep; 88(5):319-27. PubMed ID: 24010395
[TBL] [Abstract][Full Text] [Related]
95. Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series.
Jordan JT; Miller JJ; Cushing T; Seijo M; Batchelor TT; Arrillaga-Romany IC; Shih HA; Nachtigall LB; Loeffler JS; Dietrich J
Neurooncol Pract; 2018 Mar; 5(1):64-68. PubMed ID: 31385986
[TBL] [Abstract][Full Text] [Related]
96. [Gonadotroph pituitary adenomas].
Chanson P
Ann Endocrinol (Paris); 2000 Sep; 61(3):258-68. PubMed ID: 10970952
[TBL] [Abstract][Full Text] [Related]
97. Post-surgical management of non-functioning pituitary adenoma.
Cortet-Rudelli C; Bonneville JF; Borson-Chazot F; Clavier L; Coche Dequéant B; Desailloud R; Maiter D; Rohmer V; Sadoul JL; Sonnet E; Toussaint P; Chanson P
Ann Endocrinol (Paris); 2015 Jul; 76(3):228-38. PubMed ID: 26116412
[TBL] [Abstract][Full Text] [Related]
98. The epidemiology of aggressive pituitary tumors (and its challenges).
Dekkers OM; Karavitaki N; Pereira AM
Rev Endocr Metab Disord; 2020 Jun; 21(2):209-212. PubMed ID: 32361816
[TBL] [Abstract][Full Text] [Related]
99. Temozolomide in aggressive pituitary tumours and pituitary carcinomas.
McCormack A
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101713. PubMed ID: 36274026
[TBL] [Abstract][Full Text] [Related]
100. Modern imaging of pituitary adenomas.
Bashari WA; Senanayake R; Fernández-Pombo A; Gillett D; Koulouri O; Powlson AS; Matys T; Scoffings D; Cheow H; Mendichovszky I; Gurnell M
Best Pract Res Clin Endocrinol Metab; 2019 Apr; 33(2):101278. PubMed ID: 31208872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
